The concept of Richthausen LLC was developed in 2022.
We carry out R&D at all levels, from in silico and preclinical studies to registration of drugs and post-marketing, both in relation to our own innovative developments and to order.
The company assesses the risks associated with pharmaceutical development at all levels, as well as the defectiveness of medicines, medical devices and related products, develops tactics and solves the problem.
We strictly comply with the provisions of GLP, GMP and GCP, adhering to the principle of GxP: good practice in all branches of pharmacy.
We use advanced IT solutions in our work, including our own developments, which allows us to ensure the integrity, completeness and safety of data.
Our employees have long term continuous experience of academic work in federal research institutes, as well as in global pharma and in Russian companies.
Each expert has the appropriate certificates and undergoes regular re-certifications and trainings according to specifications.
Ongoing projects
4 drugs in the corporate program for import substitution of deficiency
Solid dosage forms, incl. forms with modified release of active ingredients
Liquid dosage forms, incl. suspensions
An original drug is in development
Field: infection prevention and control. Stage: Proof-of-Concept
Launch of our IT system scheduled for 2024
The launch of an IT system for continuous collection of clinical data both in the course of research and in routine medical practice is planned for 2024.
Pipeline
1
III/2024
Register of Post-Market Surveillance
2
IV/2024
Registring of two generics
3
IV/2024
Registring of finished dosage form with modified release
4
I/2025
Registring of suspension
1
II/2025
Continuation of preclinical studies of a new drug
2
III/2025
Extension of eCRF for Post-Marketing Research
3
IV/2025
Registring of a new case of generics
4
I/2026
Start of clinical trial of a new medicinal product